



НАЦИОНАЛЬНОЕ ОБЩЕСТВО
ПО ИЗУЧЕНИЮ АТЕРОСКЛЕРОЗА
RUSSIAN NATIONAL SOCIETY OF ATHEROSCLEROSIS

PROGRAM

XIII annual scientific and practical conference with international participation
of the National Society of Atherosclerosis

Atherosclerosis pandemic

December 16, 2020, Moscow

on-line

Chairpersons

Kukharchuk VV (chair)
Boytssov SA (chair)

Ezhov MV (chair)
Voevoda MI (deputy chair)

Gurevich VS (deputy chair)
Sergienko IV (deputy chair)

Secretariat Popova AB, Nozadze DN, Chubykina UV, Tmoyan NA, Prus YuA

Scientific Organizing Committee

Arabidze GG (Moscow)
Aronov DM (Moscow)
Akhmedzhanov NM (Moscow)
Balakhonova TV (Moscow)
Barbarash OL (Kemerovo)
Bershtein LL (St. Petersburg)
Bubnova MG (Moscow)
Galyavich AS (Kazan)
Dvoryashina IV (Arkhangelsk)
Drapkina OM (Moscow)
Duplyakov DV (Samara)

Eregin SYa (Yaroslavl)
Ershova AI (Moscow)
Zakirova NE (Ufa)
Zenin SA (Novosibirsk)
Karpov YuA (Moscow)
Kachkovsky MA (Samara)
Kashtalap VV (Kemerovo)
Koziolova NA (Permian)
Konovalov GA (Moscow)
Konstantinov VO (St. Petersburg)
Kosmacheva ED (Krasnodar)

Martynov AI (Moscow)
Metelskaya VA (Moscow)
Meshkov AN (Moscow)
Obrezan AG (St. Petersburg)
Oleinikov VE (Penza)
Perepech NB (St. Petersburg)
Pokrovsky SN (Moscow)
Ragino Yul (Novosibirsk)
Sadykova DI (Kazan)
Sayfutdinov RI (Orenburg)
Samokhvalov EV (Krasnoyarsk)

Skibitsky VV (Krasnodar)
Smolenskaya OG (Ekaterinburg)
Urazgildeeva SA (St. Petersburg)
Urvantseva IA (Surgut)
Filippov AE (St. Petersburg)
Khaisheva LA (Rostov-on-Don)
Khokhlov RA (Voronezh)
Chazova IE (Moscow)
Shalnova SA (Moscow)
Shaposhnik II (Chelyabinsk)
Yakushin SS (Ryazan)

AstraZeneca



акрихин
Люди заботятся о Людях

AMGEN



SANOFI

BERLIN-CHEMIE
MENARINI

Pfizer Internal Medicine

NOVARTIS



Plenary session. <i>Chairs: Kukharchuk VV, Boytsov SA</i>		
08:00–08:10	Conference opening. Kukharchuk VV, Boytsov SA	
08:10–08:30	Ezhov MV Lipidology Challenges 2020	
08:30–09:00	Peter Lansberg (Groningen, the Netherlands) Managing C(0)V(i)D risk 0 the role of lipids and statins	
09:00–09:30	Michal Vrablík (Prague, the Czech Republic) Unresolved questions of dyslipidemia management	
09:30–11:00	Scientific Symposium "Lipidology from the Red Zone" (supported by Sanofi) Chair: Konovalov GA 1. Yakovlev AN Reporting from the red zone – interviewing a patient with ACS. 2. Kashtalap VV Reporting from the red zone – interviewing a patient with severe hypercholesterolemia. 3. Vežikova NN Reporting after leaving the red zone – interviewing a patient with ACS after leaving. 4. Konovalov GA Prevention of severe course and rehabilitation after COVID-19 infection.	Scientific symposium "Through the treatment of atherogenic dyslipidemia to prolong life" (supported by Abbott) Chair: Ezhov MV 1. Alieva AS Atherogenic dyslipidemia. Approaches to solving the problem. 2. Sergienko IV Only LDL? Role of triglycerides and non-HDL cholesterol. 3. Ezhov MV "Option" Omega" – to defeat the enemy!
11:00–12:30	Scientific Symposium "Who Should Prescribe Statins Yesterday?" (supported by Pfizer) Chair: Karpov YuA 1. Karpov YuA IHD risk factors and methods of its correction. 2. Obrezan AG Who is high-intensity statin therapy indicated for? 3. Gurevich VS Myths and facts about statin therapy.	Scientific symposium "Risk factors. Knowing a little ... you have to fight " Chair: Voevoda MI 1. Galyavich AS Risk factors: known and unknown. 2. Tsygankova OV Diabetes mellitus is a cardiovascular disease. 3. Sergienko IV Control of cholesterol levels in terms of economics and strategic goals of health care (supported by AKRIKHIN). 4. Barbarash OL, Kashtalap VV Fundamental and clinical aspects of coronary calcification. Significance of comorbidity.
12:30–14:00	Scientific symposium "Myocardial infarction and ischemic stroke – how to prevent recurrence?" (supported by Amgen) Chair: Gurevich VS, Filippov AE 1. Gurevich VS New preferences for lipid-lowering therapy in primary prevention – focus on PCSK9. 2. Filippov AE PCSK9 inhibitors in secondary prevention – when and how to use? 3. Voznyuk IA Review of guidelines for lipid-lowering therapy in patients after ischemic stroke. 4. Lebedeva AYU ACS as a criterion for a very high risk of cardiovascular complications.	Scientific symposium "Fundamental aspects of atherosclerosis" Chair: Pokrovsky SN 1. Ragino Yul The role of calcification in the development of unstable atherosclerotic plaques. 2. Gabassov ZA Inflammation and atherosclerosis. 3. Larionova EE Apoptosis in the pathogenesis of atherosclerosis. Role of HDL. 4. Arefieva TI, Filatova AYU, Potekhina AV Immune markers of atherosclerosis as an age-associated disease.
14:00–15:30	Scientific symposium "Future reality in dyslipidemia treatment" (supported by Novartis) Chair: Ezhov MV 1. Zateishchikov DA Why can't we achieve the target LDL cholesterol level in all cardiac patients? 2. Sergienko IV Principles of dyslipidemia correction. 3. Ezhov MV Personalized therapy is the future reality in the dyslipidemia treatment. Results of the ORION studies group.	Scientific Symposium "Practical aspects of atherosclerosis" Chair: Shaposhnik II 1. Meshkov AN Epidemiology and genetics of familial hypercholesterolemia in Russia. 2. Balakhonova TV Diagnosis of preclinical atherosclerosis: new approaches. 3. Arabidze GG Modern laboratory diagnostics of lipid metabolism disorders for prevent development and progression of atherosclerosis. 4. Genkel VV The value of a comprehensive ultrasound assessment of carotid plaques in the diagnosis and progression of atherosclerosis.
15:30–17:00	Scientific Symposium "Optimization of cardiovascular prevention: what's new?" (supported by BerlinChemie) Chair: Bubnova MG 1. Akhmedzhanov NM Optimization of cardiovascular diseases prevention: recommendations and directions. 2. Bubnova MG Secondary prevention of cardiovascular diseases: to achieve the goal and prolong life. 3. Smolenskaya OG Clinical aspects of combination dyslipidemia therapy.	Scientific Symposium "Challenge 2020: Evolution of the significance of cardiovascular risk" (supported by Egis) Chair: Ezhov MV 1. Alieva AS "Dyslipidemia 2020. Current situation and approaches to solving the problem". 2. Sergienko IV Below the baseboard: how to achieve goals. 3. Zhernakova YuV Hyperuricemia as a CV risk factor – a new look at a familiar problem.
17:00–18:00	Scientific Symposium "Modern concept of dyslipidemia treatment: aggressive therapy or a balanced approach? " (supported by Astra Zeneca) Chairs: Bubnova MG, Yakushin SS 1. Bubnova MG Primary prevention of atherosclerotic diseases: statins today or is there time to think? 2. Khadzegova AB Statins in general medical practice: how to achieve the goal of therapy in patients with atherosclerosis.	